Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

Completed · Phase 4

Conditions studied: Overactive Bladder, Urinary Incontinence, Quality of Life

In brief

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Key facts

Study ID

NCT00224146

Run by

Watson Pharmaceuticals

People needed

2878

Starts

2004-05-01

Expected to finish

2005-05-01

Last updated by the study team

2011-11-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

You may not qualify if…

• Patients for whom Oxytrol(r) is contraindicated.
• Patients treated with Oxytrol(r) prior to participation in this study.
• Patients residing in long-term care facilities or nursing homes.

Where it is running

• Study site — Mobile, Alabama, United States
• Study site — Tucson, Arizona, United States
• Study site — Torrance, California, United States
• Study site — Rocky Hill, Connecticut, United States
• Study site — Valdosta, Georgia, United States
• Study site — Gretna, Louisiana, United States
• Study site — Bloomfield Hills, Michigan, United States
• Study site — Poughkeepsie, New York, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Tomball, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.